Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083525 · ClinicalTrials.gov registry record · Phase 1
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
A Phase 1 study, sponsored by Heidelberg Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00083525: Completed Phase 1 study, sponsored by Heidelberg Pharma.
NCT00083525 is a Phase 1 study that has completed, run by Heidelberg Pharma. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083525, a Phase 1 study, has completed, sponsored by Heidelberg Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine in patients with advanced malignancies.
Interventions
- DRUG WX-UK1 in combination with Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083525
The ClinicalTrials.gov registry entry for NCT00083525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heidelberg Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WX-UK1 in combination with Capecitabine is the first listed.
NCT00083525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083525 about?
NCT00083525 is a clinical study titled "Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies". The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine in patients with advanced malignancies.
What is the current status of trial NCT00083525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00083525?
The interventions under investigation include: WX-UK1 in combination with Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00083525?
This trial is sponsored by Heidelberg Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.